Dermatomyositis in rheumatologist's view
Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
bookPart
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
NOVA SCIENCE PUBLISHERS, INC.
Autores
ADEDUNTAN, R.
Citação
Schainberg, C. G.; Adeduntan, R.. Dermatomyositis in rheumatologist's view. In: . DERMATOLOGY RESEARCH ADVANCES: NOVA SCIENCE PUBLISHERS, INC., 2014. p.295
Resumo
Dermatomyositis (DM) is a chronic idiopathic inflammatory systemic diseasecharacterized by muscle inflammation due to perivascular involvement, usually expressedby weakness; typical cutaneous inflammation may accompany, precede or follow themuscle complaint. DM can occur at any age. In general it is believed that juveniledermatomyositis (JDM), which occurs before age 18, encompass more vasculopathy andless autoantibodies compared to the disease that affects adults. For adults, the peakincidence is close to 50 years of age, there is a female predominance and it is estimatedthat the incidence of DM is close to 9.5 cases per million people. © 2015 by Nova Science Publishers, Inc. All rights reserved.
Palavras-chave
Referências
- Dalakas, M.C., Pathogenesis and therapies of immune-mediated myopathies Autoimmun. Rev., 11, pp. 203-206
- Gutierrez, Jr.A., Wetter, D.A., Calcinosis cutis in autoimmune connective tissue diseases (2012) Dermatol. Ther., 25, pp. 195-206
- Hak, A.E., de Paepe, B., de Bleecker, J.L., Tak, P.P., de Visser, M., Dermatomyositis and polymyositis: new treatment targets on the horizon (2011) Neth. J. Med., 69, pp. 410-421
- Huber, A.M., Robinson, A.B., Reed, A.M., Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference (2012) Arthritis. Care Res., 64, pp. 546-553. , (Hoboken)
- Lam, C., Vleugels, R.A., Management of cutaneous dermatomyositis (2012) Dermatol Ther, 25, pp. 112-134
- Marie, I., Mouthon, L., Therapy of polymyositis and dermatomyositis (2011) Autoimmun. Rev., 11, pp. 6-13
- Marie, I., Morbidity and mortality in adult polymyositis and dermatomyositis (2012) Curr. Rheumatol. Rep., 14, pp. 275-285
- Pestronk, A., Acquired immune and inflammatory myopathies: pathologic classification (2011) Curr. Opin. Rheumatol., 23, pp. 595-604
- Rider, L.G., Werth, V.P., Huber, A.M., (2011) Arthritis. Care Res., 63, pp. 118-157. , Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). (Hoboken)
- Wang, D.X., Shu, X.M., Tian, X.L., Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review (2012) Clin. Rheumatol., 31, pp. 801-806
- Rosa Neto, N., Goldenstein-Schainberg, C., Juvenile dermatomyositis: review and update of the pathogenesis and treatment (2010) Rev. Bras. Reumatol., 50, pp. 299-312